Literature DB >> 9358479

Permanent atrial pacing in cardiac transplant patients.

D A Woodard1, J B Conti, R M Mills, R A Williams, A B Curtis.   

Abstract

Thirteen out of 223 consecutive cardiac transplant patients required permanent pacemaker implantation; 11 for sinus node dysfunction and 2 for complete AV block. Patients with sinus node dysfunction were considered for AAIR mode pacemakers if they had intact AV conduction defined as a Wenckebach point of > 120 beats/min. Ten of 11 patients with sinus node dysfunction had a single atrial lead placed. Atrial lead placement was most easily accomplished with a straight, active fixation lead and the use of manually curved stylets to find an optimal position in the donor atrium, although active fixation leads with a preformed atrial J were used as well. Two leads dislodged requiring revision. In contrast, only 1 of 250 atrial leads implanted in nontransplanted hearts dislodged (P < 0.0001). Transvenous endomyocardial biopsies have not caused atrial lead dislodgment. Most transplant recipients requiring permanent pacing have intact AV nodal function and require only atrial pacing. Atrial lead dislodgment requiring lead revision occurs more frequently in heart transplant recipients than in native hearts. Use of a straight active fixation lead with a manually formed curve in the stylet is useful in order to find the optimal position for pacing.

Entities:  

Mesh:

Year:  1997        PMID: 9358479     DOI: 10.1111/j.1540-8159.1997.tb06077.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  Posttransplant pacemaker placement: case series and review.

Authors:  Mark A Thompson; Hamang Patel
Journal:  Ochsner J       Date:  2010

2.  Risk factors and survival of patients with permanent pacemaker implantation after heart transplantation.

Authors:  Rasmus Rivinius; Matthias Helmschrott; Ann-Kathrin Rahm; Fabrice F Darche; Dierk Thomas; Tom Bruckner; Andreas O Doesch; Philipp Ehlermann; Hugo A Katus; Edgar Zitron
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.